






RELAX-OAB Clinical Study Overview

Study Overview



2-Year Outcomes

Symptom Reductions in UI and UF Episodes




2-Year Outcomes

Proven Durability

90%

of Test Responders
continued to respond
to therapy at 2 years



Patients reported a
mean 29-point
improvement in
quality of life



No serious device
related adverse events
were reported

References

1. Blok B, Van Kerrebroeck P, de Wachter S, et al. Three month clinical results with a rechargeable sacral neuromodulation system for the treatment of overactive bladder. *Neurourol Urodyn.* 2018;37(S2):S9–S16. doi: 10.1002/nau.23465.
2. Blok B, Van Kerrebroeck P, de Wachter S, et al. A prospective, multicenter study of a novel, miniaturized rechargeable sacral neuromodulation system: 12-month results from the RELAX-OAB study. *Neurourol Urodyn.* 2019;38(2):689–695. doi: 10.1002/nau.23892.
3. Blok B, de Wachter S, Ruffion A et al. Two years outcomes of the treatment of overactive bladder with the miniaturized, rechargeable Axonics system. *International Continence Society.* 2019 [abstract and e-poster].

Important Safety Information

[Indications, Safety and Warnings for Axonics SNM System™](#)

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France. All trademarks are the property of their respective owners. All images are the property of Boston Scientific.

**Boston
Scientific**

Advancing science for life™

www.bostonscientific.eu

© 2026 Boston Scientific Corporation
or its affiliates. All rights reserved.

URO-2464301-AA

CE 2797